CALGARY, Alberta — December 4, 2025 — Hemostemix Inc., a leader in autologous stem-cell therapeutics, has appointed Shaune Harding, OStJ, RN, as its new Director of Patient Care & Clinical Operations, reinforcing the company’s commitment to patient-centric care, clinical compliance, and the long-term advancement of its flagship therapy VesCell™ (ACP-01). Harding will oversee patient onboarding, medical-record management, real-time health-data monitoring, adverse-event reporting, and multi-year follow-up—critical components of Hemostemix’s growing regenerative-medicine platform.
Science Significance
The appointment strengthens the scientific rigor behind Hemostemix’s autologous stem-cell therapy, ACP-01, which has demonstrated statistically significant clinical benefits across ischemic diseases such as chronic limb-threatening ischemia, cardiomyopathy, congestive heart failure, and peripheral arterial disease. By integrating structured patient-journey mapping and wearable-device health analytics, Hemostemix enhances its ability to capture real-world evidence, which is increasingly essential for validating complex biologic therapies. Harding’s clinical oversight supports standardized data collection crucial for demonstrating long-term safety and efficacy in regenerative-medicine applications.
Regulatory Significance
As Hemostemix advances toward broader regulatory approvals for ACP-01, robust GxP-aligned clinical operations are indispensable. Harding’s leadership in HIPAA-compliant data handling, adverse-event escalation pathways, and structured follow-up aligns with expectations from regulators overseeing innovative biologic platforms. This role directly strengthens documentation standards required for Phase II and Phase III trial readiness, compassionate-use frameworks, and international submissions. Enhanced traceability and patient-reported outcome tracking position Hemostemix to meet strict quality, safety, and compliance thresholds for advanced therapeutic products.
Business Significance
From a commercial perspective, the expansion of the clinical-operations team signals Hemostemix’s momentum toward scaling VesCell™ (ACP-01) across multiple geographies, including The Bahamas, Florida, and Canada. By fortifying patient-care infrastructure, the company demonstrates operational maturity that supports partnerships, investor confidence, and future market entry. Harding’s experience brings strategic value as Hemostemix transitions from clinical development to commercialization pathways, enabling a more efficient patient-support pipeline and higher organizational capacity for multi-site treatment programs.
Patients’ Significance
For patients, Harding’s appointment represents enhanced continuity, safety, and personalized engagement throughout the treatment lifecycle. Her responsibilities include real-time monitoring of heart rate, sleep, activity, and exercise metrics, monthly follow-up meetings, and immediate response protocols—ensuring that individuals undergoing ACP-01 therapy receive timely intervention and sustained support. This patient-centric approach not only improves treatment adherence but also enriches the lived experience of patients confronting severe ischemic conditions, where early response and close monitoring can significantly influence outcomes.
Policy Significance
As jurisdictions like Florida adopt frameworks such as SB 1768 enabling compassionate-use of regenerative therapies, Hemostemix must align with emerging policy landscapes governing cell-based treatments. The operational enhancements tied to Harding’s role support compliance with evolving standards in areas including data governance, clinical-practice oversight, risk management, and post-treatment monitoring. These capabilities position Hemostemix to adapt to tightening regulatory expectations as regenerative medicine becomes a priority within global health-policy agendas addressing chronic cardiovascular and ischemic diseases.
Advertisement
With Shaune Harding joining as Director of Patient Care & Clinical Operations, Hemostemix strengthens its foundation in clinical excellence, regulatory preparedness, and patient-first therapeutic delivery. As the company progresses its ACP-01 platform toward wider recognition and commercialization, this appointment underscores a pivotal step in integrating clinical care, digital monitoring, and long-term safety governance—reinforcing Hemostemix’s leadership in the rapidly advancing field of autologous stem-cell therapeutics.
Source: Hemostemix Inc press release
